Lenz & Staehelin acted as Swiss counsel to the underwriters. NLS Pharmaceutics Ltd priced its USD 20 million IPO of 4,819,277 units with each unit consisting…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
